A Phase 1 interventional study of STRO-002 in Ovarian Cancer, Ovarian Carcinoma and Ovary Cancer, sponsored by Sutro Biopharma, Inc.. Completed at 27 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.
Sponsored by Sutro Biopharma, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Carcinoma, Endometrioid with a site in United States — 7 open to participants now, 13 under way, 1 of them phase 3. Carcinoma, Endometrioid · United States.
Among the 32 studies in Carcinoma, Endometrioid with a site in United States, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 1, and was the 18th registered.
46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.
Browse Carcinoma, Endometrioid studies →7 of the 32 studies in Carcinoma, Endometrioid with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+ · Women only
Faeth Therapeutics · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States, Austria, Brazil and 7 more countries
Mayo Clinic · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Carcinoma, Endometrioid studies recruiting now, 8 (73%) set no upper age limit and 3 (27%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 2
First in 2000; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 79 across 36 interventional studies indexed under Carcinoma, Endometrioid.
Median enrollment 79 across the 28 interventional studies, 365 across the 4 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 32 have an industry lead sponsor. The 10 most frequent:
Sutro Biopharma, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Sutro Biopharma, Inc. has 1 study filed under Carcinoma, Endometrioid — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Endometrioid with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03422198Phase 3University of UtahShort Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | 2026-11-30 |
| NCT04604613M.D. Anderson Cancer CenterPrediction of Recurrence Among Low Risk Endometrial Cancer Patients | 2026-12-31 |
| NCT05538897National Cancer Institute (NCI)Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | 2027-01-31 |
| NCT04291612Memorial Sloan Kettering Cancer CenterObservational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | 2027-02-26 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Carcinoma, Endometrioid with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
This study is a phase 1, open-label, multicenter, dose-escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and to evaluate the safety, tolerability, and preliminary antitumor activity of STRO-002 in adult subjects with advanced epithelial ovarian cancer (EOC), including fallopian or primary peritoneal cancer, and endometrial cancer. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this phase 1 study. Subjects enrolled in the study will be required to have progressive or recurrent disease after standard approved therapy as defined in the study eligibility criteria. The study has completed dose escalation and is currently in dose expansion, enrolling endometrial and ovarian cancer subjects.
All subjects enrolled on the study are required to have tumor tissue for determining folate receptor alpha (FolRα) expression levels, either from a prior surgery or tumor biopsy or from a biopsy performed during study screening. The testing for FolRα is done via an ICH assay. A minimum level of FolRα expression is required for enrollment for endometrial cancer but not for ovarian cancer.
Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles. Clinical evaluations and/or laboratory tests will be performed at a pre-specified schedule-weekly for cycles 1-4, and at the beginning of every cycle starting with cycle 5 as described in the schedule of assessments. Samples for PK analysis will occur at specific times on days 1, 8, and 15 of cycles 1 and 4, Day 1 of cycles 2, 3, and 5 and at the end of treatment (EOT) visit. The study requires imaging with a CT or MRI scan of the chest abdomen and pelvis at screening, every 6 weeks after enrollment for the first 18 weeks, then every 9 weeks, and at the end of treatment (EOT) visit. Additional X-rays may be required to confirm disease responses and per local institution standard of care.
Additional clinical evaluations and lab testing may occur at the discretion of the investigator.
46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.
This study's enrollment of 136 is above the median of 79 across 36 interventional studies indexed under Carcinoma, Endometrioid.
Browse Carcinoma, Endometrioid studies →Sutro Biopharma, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Compared within Carcinoma, Endometrioid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ovarian Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathological confirmation of disease under study (historical information, diagnosis, pathology report, etc)
and/or progressive disease
Dose Expansion Cohorts A and C (Ovarian Cancer):
Dose Expansion Cohort B (Endometrial Cancer):
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Escalation: STRO-002 at increasing dose levels Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg
Drug: STRO-002
intravenous antibody drug conjugate
Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)
Incidence of adverse events (AEs) observed across STRO-002 dose levels
Time frame: 18 months
Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002
Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels
Time frame: 18 months
Part 1: Define the maximum tolerated dose (MTD) of STRO-002
Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels
Time frame: 18 months
Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)
Objective response rate per RECIST 1.1
Time frame: 24 months
Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)
Objective response rate per RECIST 1.1
Time frame: 24 months
Part 1: Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax)
Measurement of maximum plasma concentration after the administration of STRO-002
Time frame: 18 months
Part 1: Characterize the PK of STRO-002 by measuring the half-life (t1/2) of STRO-002
Measurement of terminal half-life of STRO-002 after the administration of STRO-002
Time frame: 18 months
Part 1: Characterize the PK of STRO-002 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf)
Measurement of AUC to infinity (AUCinf)
Time frame: 18 months
Part 1: Characterize the PK of STRO-002 by measuring the clearance (CL)
Measurement of total body clearance
Time frame: 18 months
Part 1: Characterize the PK of STRO-002 by measuring the the steady state volume of distribution (Vss)
Measurement of steady state volume of distribution
Time frame: 18 months
Part 1: Assess the formulation of anti-drug antibodies to STRO-002
Circulating anti-drug antibodies (ADAs) formed to STRO-002
Time frame: 18 months
Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)
Number of patients with abnormal laboratory values and/or adverse events related to STRO-002 treatment
Time frame: 24 months
Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-002
Duration of response per RECIST 1.1
Time frame: 24 months
Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-002
Progression-free survival per RECIST 1.1
Time frame: 24 months
Part 2: Evaluate preliminary effect of STRO-002 treatment on CA-125 levels
Response assessment based on the Gynecologic Cancer Intergroup (GCIG) criteria
Time frame: 24 months
Part 2: Characterize the PK of STRO-002 by measuring the maximum plasma concentration (Cmax)
Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002
Time frame: 24 months
Part 2: Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)
Measurement of AUC to infinity (AUC inf)
Time frame: 24 months
Part 2: Characterize the PK of STRO-002 by measuring the clearance (CL)
Measurement of total body clearance
Time frame: 24 months
Part 1: Preliminary assessment of the anti-tumor activity of STRO-002
Objective response rate per RECIST 1.1
Time frame: 18 months
Plan to share: No
Ran from Feb 2019 to primary completion in Jun 2024, 64 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Luveltamab tazevibulin
Sutro Biopharma, Inc.